Enoblituzumab, previously known as TJ-271 or MGA271, represents an novel therapeutic targeting CD33, an antigen found predominantly on blood cells. The agent works as the two-pronged therapy, concurrently binding to https://www.targetmol.com/compound/enoblituzumab